Cost Analysis of Treatments for Guillain-Barré Syndrome
Author Information
Author(s): Jeffrey L Winters, David Brown, Elisabeth Hazard, Chester Andrzejewski Jr, Akash Chainani
Primary Institution: Mayo Clinic
Hypothesis
Is there a significant cost difference between therapeutic plasma exchange (TPE) and intravenous immunoglobulin (IVIg) in treating Guillain-Barré syndrome?
Conclusion
TPE is more cost-effective than IVIg for treating Guillain-Barré syndrome, with direct costs being more than twice as high for IVIg.
Supporting Evidence
- TPE costs $4,638.16 compared to $10,329.85 for IVIg.
- Both treatments have similar efficacy in improving patient outcomes.
- TPE reduces the length of hospital stay and ventilator support days.
Takeaway
This study shows that using TPE instead of IVIg to treat a condition called Guillain-Barré syndrome can save a lot of money while still helping patients get better.
Methodology
A cost-minimization analysis comparing a typical course of five TPEs against five IVIg infusions was performed using financial data from two institutions.
Potential Biases
Potential bias due to preference for IVIg among some physicians despite cost differences.
Limitations
The study only examines direct costs and does not account for the total costs including adverse effects.
Participant Demographics
Patients with Guillain-Barré syndrome, primarily adults.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI, $1.6 to 1.9 billion
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website